Yao Huiyu, Liu Bing, Wang Xiaoyan, Lan Yu, Hou Ning, Yang Xiao, Mao Ning
Department of Cell Biology, Institute of Basic Medical Sciences, Tai Ping Road 27, Beijing 100850, China.
Stem Cells. 2007 Jun;25(6):1423-30. doi: 10.1634/stemcells.2006-0556. Epub 2007 Mar 1.
Hemangioblast, a precursor possessing hematopoietic and endothelial potential, is identified as the blast colony-forming cell in the murine gastrulating embryos (E7.0-E7.5). Whether hemangioblast exists in the somite-stage embryos is unknown, even though hemogenic endothelium is regarded as the precursor of definitive hematopoiesis in the aorta-gonad-mesonephros (AGM) region. To address the issue, we developed a unique three-step assay of high proliferative potential (HPP) precursors. The AGM region contained a kind of HPP precursor that displayed hematopoietic self-renewal capacity and was able to differentiate into functional endothelial cells in vitro (i.e., incorporating DiI-acetylated low-density lipoprotein, expressing von Willebrand factors, and forming network structures in Matrigel). The clonal nature was verified by cell mixing assay. However, the bilineage precursor with high proliferative potential-the HPP-hemangioblast (HA)-was not readily detected in the yolk sac (E8.25-E12.5), embryonic circulation (E10.5), placenta (E10.5-E11.5), fetal liver (E11.5-E12.5), and even umbilical artery (E11.5), reflective of its strictly spatial-regulated ontogeny. Expression of CD45, a panhematopoietic marker, distinguished hematopoietic-restricted HPP-colony-forming cell from the bipotential HPP-HA. Finally, we revealed that basic fibroblast growth factor, other than vascular endothelial growth factor or transforming growth factor-beta1, was a positive modulator of the HPP-HA proliferation. Taken together, the HPP-HA represents a novel model for definitive hemangioblast in the mouse AGM region and will shed light on molecular mechanisms underlying the hemangioblast development. Disclosure of potential conflicts of interest is found at the end of this article.
血管母细胞是一种具有造血和内皮潜能的前体细胞,在小鼠原肠胚形成期胚胎(E7.0 - E7.5)中被鉴定为胚细胞集落形成细胞。尽管造血内皮被认为是主动脉 - 性腺 - 中肾(AGM)区域确定性造血的前体细胞,但尚不清楚血管母细胞是否存在于体节期胚胎中。为了解决这个问题,我们开发了一种独特的三步高增殖潜能(HPP)前体细胞检测方法。AGM区域含有一种HPP前体细胞,其具有造血自我更新能力,并且能够在体外分化为功能性内皮细胞(即摄取DiI - 乙酰化低密度脂蛋白、表达血管性血友病因子并在基质胶中形成网络结构)。通过细胞混合实验验证了其克隆性质。然而,在卵黄囊(E8.25 - E12.5)、胚胎循环(E10.5)、胎盘(E10.5 - E11.5)、胎肝(E11.5 - E12.5)甚至脐动脉(E11.5)中均未轻易检测到具有高增殖潜能的双谱系前体细胞——HPP - 血管母细胞(HA),这反映了其严格的空间调控个体发生过程。全造血标志物CD45的表达将造血受限的HPP - 集落形成细胞与双能性的HPP - HA区分开来。最后,我们发现,除血管内皮生长因子或转化生长因子 - β1外,碱性成纤维细胞生长因子是HPP - HA增殖的正向调节因子。综上所述,HPP - HA代表了小鼠AGM区域确定性血管母细胞的一种新模型,并将为血管母细胞发育的分子机制提供线索。潜在利益冲突披露见本文末尾。